Structure Therapeutics Inc. Asset Retirement Obligation, Accretion Expense
Structure Therapeutics Inc. (GPCR) reported Asset Retirement Obligation, Accretion Expense of $29.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AssetRetirementObligationAccretionExpense · last filed 2026-08-06
- Structure Therapeutics Inc. asset retirement obligation, accretion expense for the quarter ending 2026-06-30 was $19.00K.
- Structure Therapeutics Inc. asset retirement obligation, accretion expense for the quarter ending 2026-03-31 was $10.00K.
- Structure Therapeutics Inc. asset retirement obligation, accretion expense for the quarter ending 2025-12-31 was $322.00K.
- Structure Therapeutics Inc. asset retirement obligation, accretion expense for the quarter ending 2024-12-31 was -$7.00K, a 141.18% decline year-over-year.
- Structure Therapeutics Inc. asset retirement obligation, accretion expense for fiscal 2025 was $345.00K, a 8525.00% increase from fiscal 2024.
- Structure Therapeutics Inc. asset retirement obligation, accretion expense for fiscal 2024 was $4.00K, a 80.95% decline from fiscal 2023.
- Structure Therapeutics Inc. asset retirement obligation, accretion expense for fiscal 2023 was $21.00K.
| Period end | Asset Retirement Obligation, Accretion Expense 3 month | Asset Retirement Obligation, Accretion Expense 6 month | Asset Retirement Obligation, Accretion Expense 9 month | Asset Retirement Obligation, Accretion Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $29.00K 10-Q · filed 2026-08-06 | $351.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2026-03-31 | $10.00K 10-Q · filed 2026-05-07 | $332.00K derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2025-12-31 | $322.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $345.00K 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $23.00K 10-Q · filed 2025-11-06 | |||
| 2024-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.00K 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $11.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.00K 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $4.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |